SVP, Therapeutic Head, Gastroenterology
Pubblicato il 13-08-2026 - Alfasigma in Milano
Alfasigma is a privately held global healthcare company founded over 75 years ago in Italy, where it remains headquartered today in Bologna and Milan. The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa.
Over the past several years, Alfasigma has embarked on a transformative journey to become a truly global innovative healthcare company with a leading focus on Gastrointestinal (GI) health. Through significant investment in research and development, strategic acquisitions, and portfolio expansion, the company continues to strengthen its position as a leader in GI and hepatology while advancing innovation across specialty and rare disease areas.
As we continue to grow and advance our global pipeline, we are seeking a SVP, Therapeutic Area Head, Gastroenterology, to join our Global Research & Development Leadership Team. This position will be remotely based in the US, preferred east coast (EST).
Scope of the role:
The SVP Therapeutic Area Head,
Gastroenterology will serve as a senior scientific and strategic leader responsible for defining and executing the global strategy for the Gastrointestinal (GI) and hepatology therapeutic area. This individual will oversee the development and lifecycle management of the GI portfolio, ensuring alignment with corporate objectives, innovation priorities, and patient needs.
The role will drive the advancement of the GI clinical pipeline, oversee portfolio investments, and collaborate closely with stakeholders across R&D;, Regulatory, Medical Affairs, Commercial, and Business Development functions. As a recognized expert in gastroenterology and hepatology, this leader will also represent Alfasigma externally and build strong relationships with key opinion leaders, academic institutions, and scientific networks.
Your key responsibilities:
Lead the development and execution of the global Gastroenterology therapeutic area strategy aligned with corporate R&D; and portfolio priorities.Define lon